TAU targets drug-resistant ovarian tumors with nanotechnology
Ovarian cancer accounts for more deaths of American women than any other cancer of the female reproductive system. According to the American Cancer Society, one in 72 American women will be diagnosed with ovarian cancer, and one in 100 will ultimately die of the condition.
Now Prof. Dan Peer of Tel Aviv University‘s Department of Cell Research and Immunology has proposed a new strategy to tackle an aggressive subtype of ovarian cancer using a new nanoscale drug-delivery system designed to target specific cancer cells. He and his team — Keren Cohen and Rafi Emmanuel from Peer’s Laboratory of Nanomedicine and Einat Kisin-Finfer and Doron Shabbat, from TAU’s Department of Chemistry — have devised a cluster of nanoparticles called gagomers, made of fats and coated with a kind of polysugar. When filled with chemotherapy drugs, these clusters accumulate in tumors, producing dramatically therapeutic benefits.
The objective of Peer’s research is two-fold: to provide a specific target for anti-cancer drugs to increase their therapeutic benefits, and to reduce the toxic side effects of anti-cancer therapies. The study was published in February in the journal ACS Nano.
Why chemotherapy fails
According to Prof. Peer, traditional courses of chemotherapy are not an effective line of attack. Chemotherapy’s failing lies in the inability of the medicine to be absorbed and maintained within the tumor cell long enough to destroy it. In most cases, the chemotherapy drug is almost immediately ejected by the cancer cell, severely damaging the healthy organs that surround it, leaving the tumor cell intact.
But with their new therapy, Peer and his colleagues saw a 25-fold increase in tumor-accumulated medication and a dramatic dip in toxic accumulation in healthy organs. Tested on laboratory mice, the gagomer mechanism effects a change in drug-resistant tumor cells. Receptors on tumor cells recognize the sugar that encases the gagomer, allowing the binding gagomer to slowly release tiny particles of chemotherapy into the cancerous cell. As more and more drugs accumulate within the tumor cell, the cancer cells begin to die off within 24-48 hours.
“Tumors become resistant very quickly. Following the first, second, and third courses of chemotherapy, the tumors start pumping drugs out of the cells as a survival mechanism,” said Prof. Peer. “Most patients with tumor cells beyond the ovaries relapse and ultimately die due to the development of drug resistance. We wanted to create a safe drug-delivery system, which wouldn’t harm the body’s immune system or organs.”
The Latest on: Ovarian cancer
via Google News
The Latest on: Ovarian cancer
- Potential New Therapeutic Option May Combat Drug Resistance in HER2+ Breast Cancer and Ovarian Canceron December 3, 2021 at 11:45 am
A study from the Yale Cancer Center potentially introduces a drug design platform to fight drug resistance for patients with HER2-positive breast cancer and ovarian cancer.
- Cancer registry improves understanding of rare ovarian tumoron December 3, 2021 at 6:10 am
Ovarian granulosa cell tumors are a rare type of ovarian cancer that affect the ovaries and fallopian tubes, and can extend further into the pelvis and lymph nodes. Treatment typically follows the ...
- Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Canceron December 3, 2021 at 4:30 am
SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today ...
- Molecular aspects of ovarian and endometrial tumors mapped to the level of a single cellon December 2, 2021 at 11:11 pm
For the first time, researchers have determined, cell-by-cell, the genetic and epigenetic state of ovarian and endometrial tumors. Scientists at the University of North Carolina Lineberger ...
- Dr. Rose on the Importance of Genetic Testing in Ovarian Canceron December 2, 2021 at 2:03 pm
Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer. Stephen L. Rose, MD, director, Gynecologic Oncology program, Department of Obstetrics and Gynecology, University of ...
- Cytoreductive surgery before chemotherapy benefits women with recurrent ovarian canceron December 2, 2021 at 9:44 am
Cytoreductive surgery before chemotherapy led to significant and clinically meaningful OS and PFS benefits for women with recurrent ovarian cancer, according to a phase 3 study published in The New ...
- I Regret Not Recognizing my Sister's Ovarian Cancer Symptoms Sooneron December 2, 2021 at 9:11 am
A prostate cancer survivor explains his regret over not pushing his sister to visit the doctor as soon as she showed concerning symptoms, which were eventually revealed to be the stage 4 ovarian ...
- Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congresson December 2, 2021 at 4:05 am
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and blood cancers, today announced new ...
- FDA approves pafolacianine to identify ovarian cancer lesions during surgeryon November 30, 2021 at 8:01 am
The FDA approved the imaging drug pafolacianine to help surgeons identify ovarian cancer lesions.Pafolacianine (On Target Laboratories), administered via standard IV prior to surgery, is the first ...
- FDA approves pioneering drug invented at Purdue for ovarian cancer surgeryon November 30, 2021 at 6:14 am
The drug gives doctors the ability to identify additional cancerous lesions that might have been left behind in 27 percent more patients.
via Bing News